{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:53:53Z","timestamp":1791590033465,"version":"4.3.4"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Epithelioid angiomyolipoma (eAML) is an uncommon subtype of angiomyolipoma, a subset of which can demonstrate malignant behavior. While some studies have proposed histopathologic features predictive of aggressive behavior in eAML, there is limited data on the use of immunohistochemistry (IHC) and\/or next-generation sequencing (NGS) to identify biomarkers for poor clinical outcome. Moreover, there is limited data on the proposed genetic dichotomy (tuberous sclerosis complex [<jats:italic toggle=\"yes\">TSC<\/jats:italic>] alteration versus <jats:italic toggle=\"yes\">TFE3<\/jats:italic> rearrangement) of eAML. Clinicopathologic features (including purported histologic features associated with adverse outcome) of 30 eAML were recorded with IHC performed on 1 whole-slide section per tumor for the following markers (interpretations): p16 (positive or negative), p53 (wild type or mutant), TRIM63 ISH (&gt;10% as positive or \u226410% as negative), ATRX (retained or lost), and RB1 (retained or lost). NGS was performed on 23 tumors. The 30 eAML tumors were from 30 patients (23 female, 7 male) of an age range 22 to 77 years (mean=51.9\u00a0y). Clinical follow-up was available from 27 patients (mean=36\u00a0mo). The features significantly associated with metastatic disease included \u226570% atypical epithelial cells (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.04), \u22652 mitotic figures per 10 high-power fields (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.0013), atypical mitotic figures (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.0003), and necrosis (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.0213). Other features such as local invasion, vascular invasion, tumor size, and immunohistochemical profile (p16, TRIM63, p53, ATRX, and RB1) showed no significant association with the development of metastasis. Interestingly, among the 7 tumors with clinical follow-up showing <jats:italic toggle=\"yes\">TFE3<\/jats:italic> rearrangement, 5 developed metastases (OR=4.50), while 6 of 14 <jats:italic toggle=\"yes\">TSC\/MTOR<\/jats:italic> mutated tumors with clinical follow-up had metastatic disease (OR=0.222). Notably, TRIM63 ISH showed high sensitivity (100%) for eAML with <jats:italic toggle=\"yes\">TFE3<\/jats:italic> rearrangement but with poor specificity (38%). The genetic dichotomy of eAML comes in the form of <jats:italic toggle=\"yes\">TSC\/MTOR<\/jats:italic> alterations or <jats:italic toggle=\"yes\">TFE3<\/jats:italic> rearrangement elucidated by NGS, both of which may be associated with poor outcome, and therefore show potential therapeutic implications. As eAML may show overlap with <jats:italic toggle=\"yes\">TFE3<\/jats:italic>-rearranged\/<jats:italic toggle=\"yes\">TFEB<\/jats:italic>-altered renal cell carcinoma, shared TRIM63 ISH positivity for these tumor types represents an important potential diagnostic pitfall.<\/jats:p>","DOI":"10.1097\/pas.0000000000002411","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T05:00:29Z","timestamp":1745816429000},"page":"781-788","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":16,"title":["Renal Epithelioid Angiomyolipoma"],"prefix":"10.1097","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0874-8964","authenticated-orcid":false,"given":"Ankur R.","family":"Sangoi","sequence":"first","affiliation":[{"name":"Department of Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandi","family":"Lobo","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine and Urology, Kapoor Centre of Urology and Pathology, Raipur"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpy","family":"Jha","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Manipal Hospitals, Bhubaneswar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Kaushal","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, New Delhi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Tiwari","sequence":"additional","affiliation":[{"name":"Cold Spring Harbor Laboratory, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysha","family":"Mubeen","sequence":"additional","affiliation":[{"name":"University of New Mexico, Albuquerque, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Humble","sequence":"additional","affiliation":[{"name":"University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan K.","family":"Potterveld","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean R.","family":"Williamson","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmut","family":"Akgul","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Srinivas","sequence":"additional","affiliation":[{"name":"Department of Oncology and Medicine, Stanford Medical Center, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambit K.","family":"Mohanty","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"R1-20250728","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2214\/AJR.17.17973","article-title":"Renal angiomyolipoma: radiologic classification and imaging features according to the amount of fat","volume":"209","author":"Park","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"R2-20250728","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00428-013-1432-2","article-title":"Renal angiomyolipoma, fat-poor variant\u2013a clinicopathologic mimicker of malignancy","volume":"463","author":"Mehta","year":"2013","journal-title":"Virchows Arch"},{"key":"R5-20250728","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00000478-200101000-00014","article-title":"Malignant epithelioid angiomyolipoma (\u2018sarcoma ex angiomyolipoma\u2019) of the kidney: a case report and review of the literature","volume":"25","author":"Cibas","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"R6-20250728","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/00000478-199710000-00001","article-title":"Epithelioid angiomyolipoma of the kidney: a report of five cases with a prominent and diagnostically confusing epithelioid smooth muscle component","volume":"21","author":"Eble","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"R7-20250728","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2559.2009.03420.x","article-title":"Renal epithelioid angiomyolipoma: a study of six cases and a meta-analytic study. Development of criteria for screening the entity with prognostic significance","volume":"55","author":"Faraji","year":"2009","journal-title":"Histopathology"},{"key":"R8-20250728","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/00000478-200006000-00017","article-title":"Renal angiomyolipoma with epithelioid sarcomatous transformation and metastases: demonstration of the same genetic defects in the primary and metastatic lesions","volume":"24","author":"Martignoni","year":"2000","journal-title":"Am J Surg Pathol"},{"key":"R9-20250728","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/00000478-199802000-00005","article-title":"Apparent renal cell carcinomas in tuberous sclerosis are heterogeneous: the identification of malignant epithelioid angiomyolipoma","volume":"22","author":"Pea","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"R10-20250728","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ejso.2016.11.012","article-title":"Renal angiomyolipomas: at least two diseases. A series of patients treated at two European institutions","volume":"43","author":"Delhorme","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"R11-20250728","doi-asserted-by":"crossref","first-page":"372","DOI":"10.14740\/wjon1794","article-title":"Comprehensive insights into renal perivascular epithelioid cell neoplasms: from molecular mechanisms to clinical practice","volume":"15","author":"Dong","year":"2024","journal-title":"World J Oncol"},{"key":"R12-20250728","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/PAS.0b013e31817ed7a6","article-title":"Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association","volume":"33","author":"Aydin","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"R13-20250728","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/PAS.0b013e3181d90370","article-title":"Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy","volume":"34","author":"Brimo","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R14-20250728","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/modpathol.2013.72","article-title":"Epithelioid angiomyolipoma of the kidney: pathological features and clinical outcome in a series of consecutively resected tumors","volume":"26","author":"He","year":"2013","journal-title":"Mod Pathol"},{"key":"R15-20250728","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/PAS.0b013e318206f2a9","article-title":"Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification","volume":"35","author":"Nese","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"R16-20250728","doi-asserted-by":"crossref","first-page":"817","DOI":"10.5858\/arpa.2022-0127-OA","article-title":"Molecular and immunophenotypic correlates of metastatic epithelioid angiomyolipoma include alterations of TP53, RB1, and ATRX","volume":"147","author":"McCarthy","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"R17-20250728","doi-asserted-by":"crossref","first-page":"155013","DOI":"10.1016\/j.prp.2023.155013","article-title":"Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, an Indian perspective","volume":"253","author":"Aggarwal","year":"2024","journal-title":"Pathol Res Pract"},{"key":"R18-20250728","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/PAS.0b013e318031ffff","article-title":"Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum","volume":"31","author":"Argani","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"R19-20250728","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/gcc.23007","article-title":"Translocation carcinomas of the kidney","volume":"61","author":"Argani","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"R20-20250728","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/j.semdp.2021.11.001","article-title":"Immunohistochemistry for the diagnosis of renal epithelial neoplasms","volume":"39","author":"Akgul","year":"2022","journal-title":"Semin Diagn Pathol"},{"key":"R21-20250728","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/PAS.0b013e3181e8ce5b","article-title":"Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers","volume":"34","author":"Argani","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R22-20250728","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1097\/PAS.0b013e3181609914","article-title":"Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature","volume":"32","author":"Camparo","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"R23-20250728","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.prp.2012.10.013","article-title":"Diagnosis of Xp11 translocation renal cell carcinomas in adult patients under 50 years: interest and pitfalls of automated immunohistochemical detection of TFE3 protein","volume":"209","author":"Gaillot-Durand","year":"2013","journal-title":"Pathol Res Pract"},{"key":"R24-20250728","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00795-008-0423-x","article-title":"Diagnostic pitfall on the histological spectrum of adult-onset renal carcinoma associated with Xp11.2 translocations\/TFE3 gene fusions","volume":"43","author":"Kuroda","year":"2010","journal-title":"Med Mol Morphol"},{"key":"R25-20250728","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/modpathol.2017.99","article-title":"Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays","volume":"31","author":"Skala","year":"2018","journal-title":"Mod Pathol"},{"key":"R26-20250728","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/PAS.0000000000002218","article-title":"TFE3 -Rearranged PEComa\/PEComa-like neoplasms: report of 25 new cases expanding the clinicopathologic spectrum and highlighting its association with prior exposure to chemotherapy","volume":"48","author":"Argani","year":"2024","journal-title":"Am J Surg Pathol"},{"key":"R27-20250728","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/ajcp\/aqac152","article-title":"Molecular characterization of malignant renal epithelioid angiomyolipoma: a review of two cases","volume":"159","author":"Rammal","year":"2023","journal-title":"Am J Clin Pathol"},{"key":"R28-20250728","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13000-023-01298-9","article-title":"p53 aberration and TFE3 gene amplification may be predictors of adverse prognosis in epithelioid angiomyolipoma of the kidney","volume":"18","author":"Zhang","year":"2023","journal-title":"Diagn Pathol"},{"key":"R29-20250728","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1097\/01.pas.0000173232.22117.37","article-title":"Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature","volume":"29","author":"Folpe","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"R30-20250728","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/his.15304","article-title":"TFE3-rearranged nonmelanotic renal PEComa: a case series expanding their phenotypic and fusion landscape","volume":"85","author":"Agaimy","year":"2024","journal-title":"Histopathology"},{"key":"R31-20250728","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/his.15087","article-title":"PEComa with ASPSCR1::TFE3 fusion: expanding the molecular genetic spectrum of TFE3-rearranged PEComa with an emphasis on overlap with alveolar soft part sarcoma","volume":"84","author":"Zhao","year":"2024","journal-title":"Histopathology"},{"key":"R32-20250728","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1158\/2767-9764.CRC-23-0139","article-title":"Systemic treatments and molecular biomarkers for perivascular epithelioid cell tumors: a single-institution retrospective analysis","volume":"3","author":"Testa","year":"2023","journal-title":"Cancer Res Commun"},{"key":"R33-20250728","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s41379-021-00803-z","article-title":"TRIM63 is a sensitive and specific biomarker for MiT family aberration-associated renal cell carcinoma","volume":"34","author":"Wang","year":"2021","journal-title":"Mod Pathol"},{"key":"R34-20250728","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/PAS.0b013e3181f17ac0","article-title":"A distinctive subset of PEComas harbors TFE3 gene fusions","volume":"34","author":"Argani","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R35-20250728","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00428-014-1655-x","article-title":"Perivascular epithelioid cell tumor (PEComa) with TFE3 gene rearrangement: clinicopathological, immunohistochemical, and molecular features","volume":"465","author":"Shen","year":"2014","journal-title":"Virchows Arch"},{"key":"R36-20250728","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.21037\/tcr-24-60","article-title":"Management of translocation carcinomas of the kidney","volume":"13","author":"Ged","year":"2024","journal-title":"Transl Cancer Res"},{"key":"R37-20250728","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.21037\/tcr-24-737","article-title":"Non-clear cell renal cell carcinoma narrative review: where we are in 2024","volume":"13","author":"Pierro","year":"2024","journal-title":"Transl Cancer Res"},{"key":"R38-20250728","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00428-024-03855-z","article-title":"Renal epithelioid angiomyolipomas overexpress TFE3 and the TFE3-regulated gene TRIM63 in the absence of TFE3 rearrangement","volume":"485","author":"Collins","year":"2024","journal-title":"Virchows Arch"},{"key":"R39-20250728","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/PAS.0000000000000389","article-title":"Dichotomy of genetic abnormalities in PEComas with therapeutic implications","volume":"39","author":"Agaram","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R40-20250728","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/PAS.0b013e31824a8a37","article-title":"Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction","volume":"36","author":"Malinowska","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"R41-20250728","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12957-021-02462-5","article-title":"TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review","volume":"20","author":"Purwar","year":"2022","journal-title":"World J Surg Oncol"},{"key":"R42-20250728","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.urolonc.2021.09.010","article-title":"Clinical and pathological features of renal epithelioid angiomyolipoma (PEComa): a single institution series","volume":"40","author":"Saoud","year":"2022","journal-title":"Urol Oncol"},{"key":"R43-20250728","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1200\/JCO.21.01728","article-title":"-Sirolimus for patients with malignant perivascular epithelioid cell tumors","volume":"39","author":"Wagner","year":"2021","journal-title":"J Clin Oncol"},{"key":"R44-20250728","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.23.02266","article-title":"Phase II Trial of phase II trial of nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (AMPECT): long-term efficacy and safety update.","volume":"42","author":"Wagner","year":"2024","journal-title":"J Clin Oncol"},{"key":"R45-20250728","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1136\/jclinpath-2020-207372","article-title":"Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey","volume":"74","author":"Akgul","year":"2021","journal-title":"J Clin Pathol"},{"key":"R46-20250728","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1097\/PAS.0b013e31827e17cb","article-title":"TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum","volume":"37","author":"Rao","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"R47-20250728","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41379-019-0283-z","article-title":"Xp11 translocation renal cell carcinoma and clear cell renal cell carcinoma with TFE3 strong positive immunostaining: morphology, immunohistochemistry, and FISH analysis","volume":"32","author":"Yang","year":"2019","journal-title":"Mod Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:00:21Z","timestamp":1753700421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002411"}},"subtitle":["Prognostic Implications of Targeted Immunohistochemical and Molecular Markers in Conjunction with Clinicopathologic Features"],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002411","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]}}}